Menu Search
Equities

Aclaris Therapeutics Inc

8AT:FRA

Aclaris Therapeutics Inc

Actions
  • Price (EUR)12.97
  • Today's Change-2.19 / -14.42%
  • Shares traded0.00
  • 1 Year change+30.55%
  • Beta--
Data delayed at least 15 minutes, as of Feb 03 2023 07:08 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing drug candidates for immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. It is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.

  • Revenue in USD (TTM)23.50m
  • Net income in USD-82.08m
  • Incorporated2012
  • Employees75.00
  • Location
    Aclaris Therapeutics Inc640 Lee Rd Ste 200WAYNE 19087-5636United StatesUSA
  • Phone+1 (484) 324-7933
  • Fax+1 (302) 655-5049
  • Websitehttps://www.aclaristx.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.